Brief: Avenue Therapeutics Inc - On August 26, Co Received An Appeal Denied Letter From Office Of Neuroscience Of FDA
27/08/2021 14:29
Aug 27 (Reuters) - Avenue Therapeutics Inc ATXI.O :
* AVENUE THERAPEUTICS INC - ON AUGUST 26, CO RECEIVED AN
APPEAL
DENIED LETTER FROM OFFICE OF NEUROSCIENCE OF FDA
* AVENUE THERAPEUTICS INC - INTENDS TO CONTINUE TO PURSUE
REGULATORY APPROVAL FOR IV TRAMADOL
Further company coverage: ATXI.O
(((Reuters.Briefs@thomsonreuters.com);))
Recent news on Avenue Therapeutics
See all newsBrief: Axsome Therapeutics Acquires AZD7325, A Selective GABA-A Modulator For Treatment Of Epilepsy
Avenue Therapeutics Inc expected to post a loss of 57 cents a share - Earnings Preview
Brief: Avenue Therapeutics Annji Intends To Terminate License Agreement With Co
Brief: Avenue Therapeutics Receives Delist Letter From Nasdaq Under Nasdaq Listing Rule 5550(B)(1)
Avenue Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary